In COVID-19 patients, the biomarker mid-regional pro-adrenomedullin (MR-proADM), an endothelium-related peptide with vasodilatory properties, was used to evaluate the severity of endothelial dysfunction (21). The gene discussed is ADM; the disease is endothelial dysfunction.